STAT

NOVEMBER 2, 2023

A bipartisan group of senators this week introduced a bill that would permanently allow health providers to prescribe buprenorphine , a common medication used to treat opioid addiction, via telehealth. The measure, known as the Telehealth Response for E-prescribing Addiction Therapy Services Act — TREATS, for short — would permanently extend a temporary, Covid-era policy that allowed patients to receive buprenorphine remotely, without an in-person visit.

356

356

PharmaVoice

NOVEMBER 2, 2023

From Merck and J&J to AbbVie and Eisai, the oncology field has stayed consistently devoted to churning out important therapies.

265

265

STAT

NOVEMBER 2, 2023

Our minds have a weird and wondrous way of transporting us to other places and times. You might find yourself, for instance, immersed in the vivid world of a novel, or reminiscing about a potluck with close friends. These reveries can feel magical, but they’re the result of complex electric signals zipping through the brain. Now a new study shows we’re not the only ones with an imagination.

354

354

PharmaVoice

NOVEMBER 2, 2023

A challenging funding environment and lack of partnering deals have contributed to the market's ongoing troubles.

174

174

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

NOVEMBER 2, 2023

There is a persistent shortage of primary care doctors in the rural United States. Specialists, like OB-GYNs and endocrinologists, are even harder to access. According to the National Rural Health Association, there are only 30 specialists for every 100,000 residents in rural areas, compared to 263 per 100,000 in urban communities. These shortages mean that many patients must routinely drive long distances to see their doctors, or simply go without care.

327

327

PharmaTech

NOVEMBER 2, 2023

Pharmaceutical Technology Europe® speaks with Joren van der Horst from Luo Automation, a Dutch company focused on automated visual inspection solutions, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.

105

105

BioPharma Dive

NOVEMBER 2, 2023

The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.

114

114

STAT

NOVEMBER 2, 2023

Kidney transplants are the most common organ transplant procedure in the U.S., with 25,000 taking place in 2022. But for patients who receive new kidneys, the transplant is often followed by severe lifelong challenges, many of which are linked to the immunosuppression drug regimen required after surgery to ensure the body does not reject the new organ.

311

311

European Pharmaceutical Review

NOVEMBER 2, 2023

While unsolicited and burdensome, medicine shortages are an obstacle faced by the pharmaceutical industry. In 2023, a combination of factors, including increased demand (particularly for critical medicines), economic inflation, as well as international geopolitical unrest, has led to Europe’s supply chain being acutely affected. Consequently, regulators, trade groups and other organisations have worked to prevent and alleviate medicine shortages in the region.

101

101

STAT

NOVEMBER 2, 2023

Once the domain of aging TV stars, hawking health products from vitamins to diabetes supplies to a geriatric demographic, A-list celebrity endorsements of health care products are positively trendy. Migraine sufferer Lady Gaga has a deal with Nurtec ODT , a prescription drug that treats migraines from pharma company Pfizer. “This Is Us” actor Mandy Moore is contracted by Incyte to promote Opzelura , an eczema treatment.

Vaccines 307

Vaccines Diabetes 307

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharma Times

NOVEMBER 2, 2023

The NHS has already delivered over 20 million winter vaccines this year - News - PharmaTimes

Vaccines 133

Vaccines 133

STAT

NOVEMBER 2, 2023

WASHINGTON — Medicare officials are moving forward with a plan to claw back money from certain hospitals to try to remedy overpayments struck down by the Supreme Court, they announced Thursday. A federal court ordered the Department of Health and Human Services to compensate hospitals that receive discounted drugs through the 340B program for billions of dollars of underpayments, but the money had already gone out to hospitals that didn’t participate in the program.

Hospitals 278

Hospitals Drug Pricing 278

BioPharma Dive

NOVEMBER 2, 2023

The gene therapy company will move headquarters and reduce its workforce by 40%, while seeking partners for its Fabry and cell therapy research.

109

109

STAT

NOVEMBER 2, 2023

Vascular device maker Inari Medical announced plans to buy LimFlow, a company selling a last-line therapy to save legs with blocked blood flow, on Wednesday. Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success. LimFlow recently snagged Food and Drug Administration approval for its surgical system that uses a stent to connect a blocked artery to an open vein, thus allowing blood to flow through and heal injuries.

275

275

PharmExec

NOVEMBER 2, 2023

The rise in popularity of GLP-1 weight-loss drugs, such as Ozempic, Wegovy, and Mounjaro, has had a wide-reaching impact across the healthcare industry and beyond.

98

98

STAT

NOVEMBER 2, 2023

Over the past five years, two unique federal efforts have collected the health records of millions of Americans. They’ve assembled billions of clinical observations, medication logs, lab results, and more with the goal of supercharging public health research. Now, their dramatically different approaches to data sharing are coming together to put citizens’ real-world health information to work.

275

275

Pharmaceutical Technology

NOVEMBER 2, 2023

Memo’s fast track-designated candidate is currently in a Phase II trial for BKV infection, with a data readout expected in 2024.

111

111

STAT

NOVEMBER 2, 2023

When is a failure not a failure? Does the FDA have special rules for Sarepta Therapeutics? And how do you say “brash” in French? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin.

232

232

Pharma Times

NOVEMBER 2, 2023

The new AI model could potentially be applied to other cancers - News - PharmaTimes

127

127

STAT

NOVEMBER 2, 2023

Lately, we’ve seen two distinct lines at our hospitals. We would all be healthier if we brought the two lines together. The first line forms every morning before the building opens. Mothers, children, and the disabled clutch passels of documents along the sidewalk. They wait to reauthorize their Medicaid insurance.

Documentation 206

Documentation Hospitals 206

BioPharma Dive

NOVEMBER 2, 2023

The rare disease drug developer is turning to former Genentech head Alexander Hardy as the launch of its Roctavian gene therapy stumbles.

Drug Development 105

Drug Development 105

STAT

NOVEMBER 2, 2023

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning, all. Damian here with a look at the future of treating Duchenne muscular dystrophy, the departure of an influential biotech CEO, and the next phase of the GLP-1 panic.

Drug Pricing 188

Drug Pricing Drug Development 188

European Pharmaceutical Review

NOVEMBER 2, 2023

The US Food and Drug Administration ( FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). Wezlana, like Stelara, is approved to treat: Adults and children six years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; Patients six years and older with active psoriatic arthritis Adults with moderately to severely active Crohn’s disease Adults with moderately to severely active ulcerat

Biosimilars 90

Biosimilars 90

STAT

NOVEMBER 2, 2023

Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are once again enveloping the Pharmalot campus, where the official mascots are bounding about the grounds in search of creatures to annoy. As for us, we are as busy as ever hunting and gathering items of interest. We trust you have your own hectic agendas. So join us as we hoist the ever-present cup of stimulation — our choice today is roasted coconut — and attack the fast-growing to-do list.

178

178

European Pharmaceutical Review

NOVEMBER 2, 2023

Research led by the University of Sydney has found that many antibiotics recommended by the World Health Organization (WHO) had “less than 50 percent effectiveness” in treating childhood infections such as pneumonia, sepsis and meningitis. The study, published in Lancet South East Asia , analysed 6,648 bacterial isolates from 11 countries across 86 publications to review antibiotic susceptibility for common bacteria causing childhood infections.

Hospitals 88

Hospitals 88

World Pharma News

NOVEMBER 2, 2023

Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments. The expanded agreement will focus on joint cancer target identification and discovery of new therapeutic approaches in oncology.

87

87

Outsourcing Pharma

NOVEMBER 2, 2023

The US Food and Drug Administration (FDA) has approved a potassium-competitive acid blocker (PCAB) as a new treatment for the healing of all grades of erosive esophagitis.

89

89

The Script

NOVEMBER 2, 2023

Are you a military veteran? Our team at Rx relief weighs in on why veterans should consider a career in the pharmaceutical industry.

98

98

Pharmaceutical Technology

NOVEMBER 2, 2023

Generate:Biomedicines has entered a strategic collaboration with Roswell Park to accelerate the development of new oncology therapies

97

97

Welltopia Pharmacy

NOVEMBER 2, 2023

Detox for Weight Loss: Shed Pounds, Boost Health Introduction Concept of detoxification. Detoxification, often referred to as detox, is a The post Detox for Weight Loss: Shed Pounds, Boost Health first appeared on Welltopia Compounding Pharmacy.

Compounding Pharmacies 81

Compounding Pharmacies Compounding 81

PharmaTech

NOVEMBER 2, 2023

Predictive modeling facilitates the identification of coformers, cocrystal components, and complexing agents.

104

104

Pharmaceutical Technology

NOVEMBER 2, 2023

The UK MHRA authorises Pfizer’s Litfulo (ritlecitinib), to treat severe alopecia areata in people aged 12 years and above.

98

98

Express Pharma

NOVEMBER 2, 2023

The future of Crohn’s disease (CD) therapy will be highly dynamic and competitive, with the advancement of developing novel mechanisms of action, both in biologics and with small molecule agents. Though the entry of biosimilars will contract the market, significant growth is expected over the next 8-10 years, driven by the launch of new assets. Against this backdrop, the CD drug sales across the eight-major markets (8MM*) are set to increase at a compound annual growth rate (CAGR) of 4.7 per cen

Biosimilars 77

Biosimilars Compounding 77

PharmaTech

NOVEMBER 2, 2023

Pharmaceutical Technology Europe® spoke with Carlos Rial Calvo from FABRX, a pharmaceutical 3D printing company, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.

64

64

BioPharma Dive

NOVEMBER 2, 2023

Stock selloffs across the medical device sector have erased hundreds of billions of dollars in market value. But medtech executives argue GLP-1 drug demand will complement, not cannibalize, their sales.

62

62